Pulmonary eosinophilia after substitution of aerosol for oral corticosteroid therapy.
Three patients with chronic asthma developed pulmonary eosinophilia while oral prednisolone was being withdrawn after the introduction of treatment with beclomethasone dipropionate aerosol. These observations suggest that the development of pulmonary eosinophilia in patients with chronic asthma can be prevented by the systemic administration of corticosteroids, but not by a corticosteroid aerosol given by inhalation. It is considered that radiological examination of the chest should be carried out at frequent intervals during and for a few months after the substitution of corticosteroid aerosol therapy for oral corticosteroid therapy in order to ensure that those patients who are liable to develop pulmonary eosinophilia will be identified at an early stage. These precautions are even more essential when there is a previous history of pulmonary eosinophilia.
D000284:Administration, Oral; D000336:Aerosols; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D001249:Asthma / Q000150:complications* / Q000188:drug therapy; D001507:Beclomethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D020680:Bronchoscopes; D004804:Eosinophils; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D011657:Pulmonary Eosinophilia / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D011859:Radiography; D012138:Respiratory Therapy
D000336:Aerosols; D011239:Prednisolone; D001507:Beclomethasone; D008775:Methylprednisolone